Table 2.
Diagnostic performance of CEUS LI-RADS for HCC
| Study | Study type | Contrast agent | Diagnostic criteria | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|
| Terzi et al. [61] (2018) | Retrospective | SonoVue | LR-5 | 62.0 | 96.0‡ |
| Li et al. [62] (2019) | Retrospective | SonoVue | LR-5 | 89.1 | 80.4 |
| Makoyeva et al. [63] (2020) | Retrospective | Definity | LR-5 | 86.0 | 96.0 |
| LR-5/TIV | 92.0 | 96.0 | |||
| Huang et al. [17],* (2020) | Retrospective | SonoVue | LR-5 | 73.3 | 97.1 |
| Zheng et al. [64] (2020) | Retrospective | SonoVue | LR-5 | 75.0 | 96.0 |
| Modified LR-5† | 85.0 | 94.0 | |||
| Strobel et al. [19] (2021) | Prospective | Unmentioned | LR-5 | 65.2 | 78.6 |
| Li et al. [65] (2021) | Retrospective | SonoVue | LR-5 | 75.5 | 93.9 |
| Ding et al. [66] (2021) | Retrospective | SonoVue | LR-5 | 75.6 | 93.8 |
| Li et al. [67] (2021) | Retrospective | SonoVue | LR-5 | 49.6–64.3 | 85.3–91.7 |
| Ghiuchici et al. [68] (2021) | Retrospective | SonoVue | LR-5 | 71.9 | 94.3 |
| Schellhaas et al. [20] (2021) | Prospective | Unmentioned | LR-5/TIV | 64.0 | 78.9 |
| Zhou et al. [18] (2022) | Prospective | SonoVue | LR-5 | 38.6–63.6 | 92.7–100.0 |
CEUS, contrast-enhanced ultrasound; LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; TIV, tumor in vein.
*
All lesions are 20 mm or smaller.
†
Lesions with non-rim APHE and early but not punched-out washout are classified into LR-5 rather than LR-M.
‡
Recalculated based on the data reported.